SCHEDULE: Ikarian Capital Discloses 12.6% Stake in Quoin Pharma

Ikarian Capital and Neil Shahrestani have reported a 12.6% beneficial ownership stake in Quoin Pharmaceuticals, Ltd. through American Depositary Shares.

Summary

• Ikarian Capital, LLC and Neil Shahrestani (Reporting Persons) have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Quoin Pharmaceuticals, Ltd.
• The filing reports an aggregate beneficial ownership of 211,538 American Depositary Shares (ADS) of Quoin Pharmaceuticals, Ltd.
• This represents 12.6% of the issuer's class of securities, based on 1,683,627 ADS outstanding as of January 31, 2026.
• The Reporting Persons hold shared voting and dispositive power over all 211,538 ADS.
• Ikarian Capital, an investment adviser, manages the Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts which are the record owners of the securities.
• Neil Shahrestani indirectly controls Ikarian Capital and is therefore deemed to beneficially own the securities.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a substantial 12.6% beneficial ownership by a specialized healthcare investment firm like Ikarian Capital suggests a strong conviction in Quoin Pharmaceuticals' prospects.

Positives

• A significant institutional investor, Ikarian Capital, holds a 12.6% stake, potentially signaling confidence in Quoin Pharmaceuticals, Ltd.

Negatives

• NA

Risks

• The Reporting Persons disclaim that the filing implies they are acting as a group for the purpose of acquiring, holding, or disposing of securities, or that they are a member of any such group, for Section 13(d) or 13(g) purposes.

Future Outlook

NA

Management Comments

• To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.
• Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.
• Each of the Reporting Persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purpose of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the issuer or otherwise with respect to the issuer or any securities of the issuer or (ii) a member of any group with respect to the issuer or any securities of the issuer.

Industry Context

StockSavvy.ai notes that a significant stake (over 5%) by an institutional investment adviser like Ikarian Capital in a pharmaceutical company like Quoin Pharmaceuticals often signals a long-term investment thesis, potentially based on the company's drug pipeline, market potential, or strategic direction. Such disclosures can attract attention from other institutional investors and retail traders, especially in the biotech sector where clinical trial results and regulatory approvals are key catalysts.

Comparison to Industry Standards

• StockSavvy.ai observes that institutional ownership levels vary widely across the pharmaceutical and biotechnology sectors. A 12.6% stake by a single investment firm is a substantial position, indicating a high conviction investment.
• This level of ownership is comparable to the initial significant positions taken by funds such as Perceptive Advisors or RA Capital Management in smaller-cap biotechs, often preceding periods of increased market visibility or strategic developments.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially attract more investment, positively impacting share price.
• Company Management: A large institutional holder may exert influence through engagement, though the filing states the stake is not for changing or influencing control.

Key Dates

Recommendation

The filing indicates a significant institutional stake, which is generally a positive signal of investor confidence. However, a Schedule 13G filing primarily provides ownership information and does not offer new operational or financial data about Quoin Pharmaceuticals. While the institutional interest is noteworthy, without additional fundamental analysis of the company's performance, pipeline, and market position, a "hold" recommendation is prudent for existing investors, and further due diligence is advised for potential new investors.

Keywords

Quoin Pharmaceuticals, Ikarian Capital, Neil Shahrestani, Schedule 13G, beneficial ownership, American Depositary Shares, ADS, institutional investment, biotech, pharmaceutical